# Saranas

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/saranas

- Industry: Medical Devices & Equipment
- Headquarters: Houston, US
- Website: www.saranas.com
- Total disclosed funding: $13M
- Latest round: Series B (Jul 19, 2021)
- Investors on record: 2

## About

Saranas, Inc. develops innovative medical technologies aimed at improving patient outcomes during minimally invasive procedures. Their flagship product focuses on real-time detection of complications, enhancing safety in healthcare.Founded in 2013 and headquartered in Houston, US, Saranas, Inc. specializes in medical technology solutions that enhance patient safety during procedures. The company has successfully raised a total of USD 12.8 mn, with the most recent funding event being a Series B round on July 19, 2021, led by Baird Capital Partners and S3 Ventures. Mehdi Razavi is one of the key figures associated with the company's founding, contributing to its strategic vision and growth.Saranas, Inc. offers a suite of medical technologies designed to detect complications in real-time during minimally invasive procedures. Their primary product provides healthcare professionals with critical information to enhance decision-making and improve patient safety. The company targets a wide array of healthcare providers, ensuring that their solutions cater to various healthcare settings and specialties, thereby facilitating better patient care across different regions.Saranas, Inc. generates revenue primarily through the sale of its medical devices and associated technologies to healthcare providers. The company engages in direct transactions with hospitals and clinics, which may involve multi-year agreements ensuring ongoing service and support. Their revenue model is structured around the sale of devices that integrate into existing medical procedures, thereby establishing long-term relationships and ongoing demand for their products.Looking ahead, Saranas, Inc. plans to utilize the USD 12.8 mn raised in Series B funding to enhance their product development initiatives, focusing on launching new technologies that further improve patient outcomes in healthcare. The company aims to expand its market presence in North America and Europe by 2023, targeting healthcare systems that prioritize advanced monitoring solutions. This funding will support the development and commercialization of innovative products designed to address emerging needs in patient safety and procedural efficiency.

## Funding rounds

- Series B, Jul 19, 2021, $13M — Baird Capital Partners, S3 Ventures

## Investors

- Baird Capital Partners (https://capitalatlas.ai/funds/baird-capital-partners) — Series B
- S3 Ventures (https://capitalatlas.ai/funds/s3-ventures) — Series B